Oxford, UK – 31 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that the Group’s Chief Executive Officer John Dawson has been awarded a CBE (Commander of the Order of the British Empire) for services to… Read More
Oxford, UK – 14 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces the appointment of Ms Catherine Moukheibir to the Board as an Independent Non-Executive Director with effect from today. Ms Moukheibir has extensive international experience in finance, capital markets… Read More
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More
Oxford, UK – 13 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with Arcellx, Inc. (“Arcellx”), a Gaithersburg MD.-based biotechnology company developing novel, adaptive and controllable cell… Read More
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK – 19 October 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that Boehringer Ingelheim has exercised its option to… Read More
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More
Oxford Biomedica delivers record first half results Oxford, UK – 22 September 2021: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2021. John Dawson, Oxford Biomedica’s Chief Executive Officer, said:… Read More
London, UK – 1 September 2021: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2021 on Wednesday 22 September 2021. A briefing for analysts will be held at 13:00 BST / 08:00 EST on… Read More
Oxford, UK – 15 July, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that Dr. Michael Hayden has been appointed to the Group’s Board as a Non-Executive Director, effective today. Dr. Hayden was the President of Global… Read More
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More
London, UK – 27 April 2021: Oxford Biomedica plc (“Oxford Biomedica”, “the Company” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, gives notice that copies of the 2020 Annual report and accounts and the… Read More
Oxford Biomedica plc Preliminary results for the year ended 31 December 2020 Saving Lives Oxford, UK – 15 April 2021: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading cell and gene therapy group, today announces its preliminary results for the year ended 31 December 2020. John… Read More